These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 19342505)
1. Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays. Krasowski MD; Siam MG; Iyer M; Pizon AF; Giannoutsos S; Ekins S Clin Chem; 2009 Jun; 55(6):1203-13. PubMed ID: 19342505 [TBL] [Abstract][Full Text] [Related]
2. Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays. Krasowski MD; Siam MG; Iyer M; Ekins S Ther Drug Monit; 2009 Jun; 31(3):337-44. PubMed ID: 19333148 [TBL] [Abstract][Full Text] [Related]
3. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. Krasowski MD; Pizon AF; Siam MG; Giannoutsos S; Iyer M; Ekins S BMC Emerg Med; 2009 Apr; 9():5. PubMed ID: 19400959 [TBL] [Abstract][Full Text] [Related]
4. Cross-reactivity studies and predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays. Petrie M; Lynch KL; Ekins S; Chang JS; Goetz RJ; Wu AH; Krasowski MD Clin Toxicol (Phila); 2013 Feb; 51(2):83-91. PubMed ID: 23387345 [TBL] [Abstract][Full Text] [Related]
5. Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays. Martinez-Brokaw CD; Radke JB; Pierce JG; Ehlers A; Ekins S; Wood KE; Maakestad J; Rymer JA; Tamama K; Krasowski MD BMC Clin Pathol; 2019; 19():2. PubMed ID: 30820187 [TBL] [Abstract][Full Text] [Related]
7. Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays. Krasowski MD; Ekins S J Cheminform; 2014; 6():22. PubMed ID: 24851137 [TBL] [Abstract][Full Text] [Related]
8. A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing. Reschly-Krasowski JM; Krasowski MD Acad Pathol; 2018; 5():2374289518811797. PubMed ID: 30480089 [TBL] [Abstract][Full Text] [Related]
9. Approaches to minimizing interference by cross-reacting molecules in immunoassays. Miller JJ; Valdes R Clin Chem; 1991 Feb; 37(2):144-53. PubMed ID: 1993317 [TBL] [Abstract][Full Text] [Related]
10. Tacrolimus metabolite cross-reactivity in different tacrolimus assays. Murthy JN; Davis DL; Yatscoff RW; Soldin SJ Clin Biochem; 1998 Nov; 31(8):613-7. PubMed ID: 9876892 [TBL] [Abstract][Full Text] [Related]
11. Determination of designer drug cross-reactivity on five commercial immunoassay screening kits. Regester LE; Chmiel JD; Holler JM; Vorce SP; Levine B; Bosy TZ J Anal Toxicol; 2015 Mar; 39(2):144-51. PubMed ID: 25492523 [TBL] [Abstract][Full Text] [Related]
12. Lack of Detection of New Amphetamine-Like Drugs Using Conventional Urinary Immunoassays. Begeman A; Franssen EJF Ther Drug Monit; 2018 Feb; 40(1):135-139. PubMed ID: 29194289 [TBL] [Abstract][Full Text] [Related]
13. Quetiapine cross-reactivity with plasma tricyclic antidepressant immunoassays. Caravati EM; Juenke JM; Crouch BI; Anderson KT Ann Pharmacother; 2005 Sep; 39(9):1446-9. PubMed ID: 16046487 [TBL] [Abstract][Full Text] [Related]
14. False positive amphetamines and 3,4-methylenedioxymethamphetamine immunoassays in the presence of metoprolol-two cases reported in clinical toxicology. Leclercq M; Soichot M; Delhotal-Landes B; Bourgogne E; Gourlain H; Mégarbane B; Labat L J Anal Toxicol; 2020 Mar; 44(2):200-205. PubMed ID: 31384953 [TBL] [Abstract][Full Text] [Related]
15. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine. Fraser AD; Howell P J Anal Toxicol; 1998; 22(1):50-4. PubMed ID: 9491969 [TBL] [Abstract][Full Text] [Related]
16. Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse. Beck O; Rausberg L; Al-Saffar Y; Villen T; Karlsson L; Hansson T; Helander A Drug Test Anal; 2014 May; 6(5):492-9. PubMed ID: 24665024 [TBL] [Abstract][Full Text] [Related]
17. Hair analysis by immunological methods from the beginning to 2000. Spiehler V Forensic Sci Int; 2000 Jan; 107(1-3):249-59. PubMed ID: 10689577 [TBL] [Abstract][Full Text] [Related]
18. Modeling Tanimoto Similarity Value Distributions and Predicting Search Results. Vogt M; Bajorath J Mol Inform; 2017 Jul; 36(7):. PubMed ID: 28032955 [TBL] [Abstract][Full Text] [Related]
19. MetMaxStruct: A Tversky-Similarity-Based Strategy for Analysing the (Sub)Structural Similarities of Drugs and Endogenous Metabolites. O'Hagan S; Kell DB Front Pharmacol; 2016; 7():266. PubMed ID: 27597830 [TBL] [Abstract][Full Text] [Related]
20. A simple and robust method for broad range screening of hair samples for drugs of abuse using a high-throughput UHPLC-Ion Trap MS instrument. Musile G; Mazzola M; Shestakova K; Savchuk S; Appolonova S; Tagliaro F J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122263. PubMed ID: 32693369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]